TANVEX BIOPHARMA, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.2 TWD | +1.29% |
|
+3.16% | -39.78% |
| May. 28 | Tanvex BioPharma, Inc.(TWSE:6541) dropped from S&P Global BMI Index | CI |
| May. 13 | Tanvex BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2022 | 22.4 727.26 | Sales 2023 | 61.41 1.99K | Capitalization | 8.71B 283B |
|---|---|---|---|---|---|
| Net income 2022 | -1.64B -53.27B | Net income 2023 | -2.14B -69.37B | EV / Sales 2022 | 599,427,887 x |
| Net Debt 2022 | 1.05B 34.18B | Net Debt 2023 | 1.35B 43.86B | EV / Sales 2023 | 163,906,538 x |
| P/E ratio 2022 |
-7.54
x | P/E ratio 2023 |
-3.93
x | Employees | 167 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.81% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.29% | ||
| 1 week | +3.16% | ||
| 1 month | -16.42% | ||
| 3 months | -36.67% | ||
| 6 months | -44.63% | ||
| Current year | -39.78% |
1 week
37.90
39.80
1 month
35.0546.60
Current year
35.0566.50
1 year
35.0580.80
3 years
35.05245.22
5 years
35.05299.78
10 years
35.051 034.21
| Managers | Title | Age | Since |
|---|---|---|---|
Kuan Hao Lin
DFI | Director of Finance/CFO | - | 22-02-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
ALLEN Chao
FOU | Founder | 78 | 13-05-07 |
Ta Meng Tseng
BRD | Director/Board Member | 66 | 13-10-05 |
Chih Chuan Chen
BRD | Director/Board Member | - | 13-10-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 7 M€ | +0.11% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 39.2 | +1.29% | 83,819 |
| 24-05-30 | 38.7 | +0.91% | 79,029 |
| 24-05-29 | 38.35 | -1.67% | 105,765 |
| 24-05-28 | 39 | +1.17% | 92,493 |
| 24-05-27 | 38.55 | +1.45% | 74,276 |
End-of-day quote Taiwan S.E., May 30, 2024
More quotes
Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Companyâs product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.
Calendar
2024-06-18
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -39.78% | 198M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- 6541 Stock
